Stephens analyst Sudan Loganathan reiterated an Overweight rating and $5.00 price target on Actinium Pharma (NYSE: ATNM).The analyst commented: "ATNM ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE